Revolution Medicines, Inc. Warrant Q4 FY2024 earnings call

Mark Goldsmith discussed the mission to revolutionize treatment for RAS-addicted cancers via discovery, development, and delivery pillars. In 2024, progress was made in advancing RAS(ON) inhibitor portfolio with clinical data on daraxonrasib, elironrasib, and zoldonrasib. Key 2025 priorities include executing pivotal trials for daraxonrasib in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), advancing mutant selective inhibitors (elironrasib and zoldonrasib), progressing earlier-stage pipeline (including RMC-5127), and building commercial capabilities in preparation for potential launch of daraxonrasib.

No specific financial performance by product segment data provided in the transcript.

Full year 2025 GAAP net loss is expected to be between $840 million and $900 million. This includes estimated non-cash stock-based compensation expense of $115 million to $130 million. The increase in net loss is due to increased expenses from the progression and expansion of clinical development programs, including ongoing and planned registrational studies, and increased commercial preparation efforts.

Forward-looking statements are subject to many risks and uncertainties, as noted in the transcript, but no detailed discussion of specific risks provided within the call content.

Q: Can you walk us through the decision to move forward with 2 Phase III studies in earlier line PDAC?

A: Mark Goldsmith explained it's based on data showing potential of daraxonrasib and the aim to own the PDAC space.

Q: What about the proposed pivotal study in the adjuvant setting for resectable PDAC?

A: Dr. Wei Lin commented on the proportion of resectable PDAC cases and challenges with early detection.

Q: Thoughts on colorectal cancer data disclosure cadence?

A: Mark Goldsmith stated no guidance provided yet but they continue studying colorectal cancer.

Q: Phase I study in PDAC and OS data update?

A: Mark Goldsmith mentioned OS data from the Phase I study is immature and will be updated as it matures.

Q: First-line lung cancer opportunity and data disclosure?

A: Steve Kelsey discussed RAS-mutant lung cancer subsets and data release in tranches as data accumulates.

Q: Dosing duration for daraxonrasib in adjuvant PDAC study?

A: Mark Goldsmith noted trial design details are early and will be addressed in due course.

Q: Collaboration opportunities with daraxonrasib?

A: Mark Goldsmith mentioned ongoing preclinical and clinical collaborations, including with Tango Therapeutics.

Q: Additional data needed for zoldonrasib pivotal trials?

A: Mark Goldsmith said they are evaluating zoldonrasib in combinations and expect additional clinical data mid-year.

Q: Completion of second-line PDAC study and potential approval?

A: Mark Goldsmith discussed enrollment progress in the second-line PDAC trial and regulatory considerations.